| Items
101 ~ 120 of 26004, Page 6 of 1301 |
|
|
|
|
|
|
|
104. New Research from Merck’s Broad Oncology Clinical Development Program to be Presented at 2019 ASCO Annual Meeting |
|
First-Time Data from POLO Trial Evaluating LYNPARZA ® (olaparib) in Germline BRCA-Mutated Metastatic Pancreatic Cancer in Plenary Session and ASCO Press Program / KEYTRUDA ® (pembrolizumab) Five-Year Survival Data in Advanced Non-Small Cell Lung Cancer (NSCLC) from KEYNOTE-001 Trial in ASCO Press Program / Overall Survival Data for KEYTRUDA in Metastatic Renal Cell Carcinoma (RCC), Recurrent/Metastatic Head and Neck Cancer and Advanced Gastric or Gastroesophageal Junction (GEJ) Cancer |
|
05/15/2019
MERCK |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
115. Novel Artificial Intelligence Method Predicts Future Risk of Breast Cancer |
|
A new tool using advanced AI methods can predict a woman’s future risk of breast cancer. / Researchers used almost 90,000 screening mammograms from about 40,000 women to train, validate and test the new breast cancer risk-assessment model. / The model performs equally well across diverse races, ages and family histories. |
|
05/07/2019
Radiological Society of North America |
|
|
|
|
|
|
|
|
119. Women with Coronary Artery Wall Thickness at Risk for Heart Disease |
|
Researchers used CCTA and Framingham scores to assess coronary artery disease in 62 women and 62 men at low to intermediate risk of heart disease. / Vessel wall thickness, as measured by MRI, was the strongest variable associated with coronary artery disease in women. / The results point to a potential future role for vessel wall thickness measurements in identifying opportunities for early lifestyle changes or treatment. |
|
04/25/2019
Radiological Society of North America |
|
|
|
